Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms ...

The objective is to use “data, technology, and science to make self-care more precise”, with digital diagnostics ... consistently looking for health solutions that go beyond traditional ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF ... “Chronos-PD,” could accelerate the discovery of new diagnostic tools as well as the identification and development ...

Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael ... The initiative, named Chronos-PD, could lead to the discovery of new ...

Spanish pharma Grifols is leveraging its massive collection ... “The hope is to accelerate and ultimately develop new diagnostics and disease-modifying therapeutics that could mitigate or ...

leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...